Abstracts Archive - Page 1293 of 2607 - ACR Meeting Abstracts

Abstract Number: 1600 • 2018 ACR/ARHP Annual Meeting
Psychometric Properties of the Assessment of Spa International Society Health Index in Patients with Active As/Radiographic Axial Spa in a Phase 3 Clinical Study
Uta Kiltz¹, Désirée van der Heijde², Annelies Boonen^3,4, Lianne S. Gensler⁵, Theresa Hunter⁶, Yan Dong⁶, Kathleen Wyrwich⁶, Hilde Carlier⁶ and Jürgen Braun^1,7, ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Leiden University Medical Centre, Leiden, Netherlands, ³Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Center, Maastricht, Netherlands, ⁴Caphri Research Institute, Maastricht, Netherlands, ⁵University of California San Francisco, San Francisco, CA, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Ruhr Universität Bochum, Bochum, Germany
Background/Purpose: The Assessment of SpA international Society Health Index (ASAS HI) was developed to assess function, disability, and health in patients (pts) with SpA. This…
Abstract Number: 1601 • 2018 ACR/ARHP Annual Meeting
Impact of Clinical Specialty Setting and Geographic Regions on Disease Management in Patients with Psoriatic Arthritis: Results from a Cross-Sectional Observational Study in the United States
Philip J. Mease¹, Clive Liu², Evan Siegel^3,4, Heather Richmond⁵, Meijing Wu⁶, Liang Chen⁶, Kevin Douglas⁶ and Benjamin Lockshin⁷, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Bellevue Dermatology Clinic, Bellevue, WA, ³Georgetown University, Washington, DC, ⁴Arthritis and Rheumatism Associates, Rockville, MD, ⁵Clear Dermatology, Houston, TX, ⁶AbbVie Inc., North Chicago, IL, ⁷US Dermatology Partners, Rockville, MD
Background/Purpose: In patients (pts) with psoriatic arthritis (PsA), early diagnosis and effective treatment has been shown to decrease functional disability and structural progression (Gladman DD,…
Abstract Number: 1602 • 2018 ACR/ARHP Annual Meeting
Disease Characteristics, Quality of Life, and Work Productivity By Enthesitis Sites: Real-World Data from the US Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J. Mease¹, Mei Liu², Sabrina Rebello³, Winnie Hua², Robert R. McLean², Peter Hur⁴ and Alexis Ogdie⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Corrona, LLC, Waltham, MA, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, New Jersey, USA, East Hanover, NJ, ⁵Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Prior studies showed psoriatic arthritis (PsA) patients with enthesitis had greater disease burden than patients without enthesitis, yet it is unknown whether the impact…
Abstract Number: 1603 • 2018 ACR/ARHP Annual Meeting
Gender-Specific Differences in Chinese Patients with Ankylosing Spondylitis
Weiping Kong¹, Caroline Jefferies², Thomas Learch³, Xiaowei Gan¹, Jinrui Cui⁴, Yuan Xu¹, Dier Jin¹, Yingze Zhang¹, Jianming Wang¹, Qingwen Tao¹, Xiaoping Yan¹, Michael Weisman⁵ and Mariko Ishimori⁶, ¹China-Japan Friendship Hospital, Beijing, China, ²Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA, ³Radiology, Cedars-Sinai Medical Center, Los Angeles, CA, ⁴Cedars-Sinai Medical Center, Los Angeles, CA, ⁵Harbor UCLA Medical Center, Los Angeles, CA, ⁶Medicine, Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: Growing evidence suggests gender-specific differences in the phenotypes of ankylosing spondylitis (AS). However, a literature search failed to reveal evidence of such differences in…
Abstract Number: 1604 • 2018 ACR/ARHP Annual Meeting
Impact of Time to Minimal Disease Activity and Quality of Life One Year after Diagnosis of Psoriatic Arthritis
Kim Wervers¹, Jolanda J. Luime¹, Ilja Tchetverikov², Andreas H. Gerards³, M.R. Kok⁴, Cathelijne W. Y. Appels⁵, Wiebo L. van der Graaff⁶, Johannes H. L. M. van Groenendael⁷, Lindy-Anne Korswagen³, Josien J Veris-van Dieren⁸, JMW Hazes¹ and Marijn Vis¹, ¹Erasmus Medical Centre, Rotterdam, Netherlands, ²Albert Schweitzer Hospital, Dordrecht, Netherlands, ³Sint Franciscus Vlietland Group, Rotterdam, Netherlands, ⁴Rheumatology, Maasstad Ziekenhuis, Rotterdam, Netherlands, ⁵Rheumatology, Amphia Hospital, Breda, Netherlands, ⁶Rheumatology, Rivas hospital, Gorinchem, Netherlands, ⁷Rheumatology, Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁸Rheumatology, Reumazorg Zuid West Nederland, Goes, Netherlands
Background/Purpose: From previous cross-sectional research we know that minimal disease activity (MDA) is associated with better health-related quality of life (HRQoL) in psoriatic arthritis (PsA).…
Abstract Number: 1605 • 2018 ACR/ARHP Annual Meeting
Prevalence of Anterior Uveitis in Patients with Spondyloarthropathy in a Single US Academic Center: A Retrospective Study from Routine Care
Ofelya Gevorgyan¹, Rebecca D. Sarran², Pauline T. Merrill², Joel A. Block³ and Isabel Castrejon¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Ophthalmology, Rush University Medical Center, Chicago, IL, ³Division of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Acute anterior uveitis (AAU) is the most common extra-articular feature of spondyloarthropathies (SpA) over the course of the disease. Around 33% of patients with…
Abstract Number: 1606 • 2018 ACR/ARHP Annual Meeting
The 66/68 Joint Count for the Measurement of MSK Disease Activity/Peripheral Joint Activity in Psa: A Grappa-Omeract Working Group Initiative
Ali Duarte-Garcia¹, Lihi Eder², Niti Goel³, Robin Christensen⁴, Maarten de Wit⁵, Oliver FitzGerald⁶, Dafna D Gladman⁷, Richard Holland⁸, Ying Ying Leung⁹, Christine Lindsay¹⁰, Neil McHugh¹¹, Philip J. Mease¹², Ana-Maria Orbai¹³, Beverly Shea¹⁴, Vibeke Strand¹⁵, William Tillett¹⁶, Laura C. Coates¹⁷ and Alexis Ogdie¹⁸, ¹Mayo Clinic College of Medicine and Science, Rochester, MN, ²Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada, ³Kezar Life Sciences; Duke University School of Medicine, Durham, NC, ⁴Musculoskeletal Statistics Unit, The Parker Institute, Bispebjerg and Frederiksberg, Denmark, ⁵EULAR standing committee of PARE, Zurich, Switzerland, ⁶Department of Rheumatology, St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, ⁷University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁸Royal Prince Alfred Hospital Medical Centre, Sydney, Australia, ⁹North District Hospital, Hong Kong, China, ¹⁰Medical Affairs, Amgen Inc, Thousand Oaks, CA, ¹¹Rheumatology, Royal National Hospital, Bath, Great Britain, ¹²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ¹³Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁴University of Ottawa, Ottawa, ON, Canada, ¹⁵Stanford University School of Medicine, Palo Alto, CA, ¹⁶Royal National Hospital for Rheumatic Diseases and University of Bath, Bath, United Kingdom, ¹⁷University of Oxford, Oxford, United Kingdom, ¹⁸Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: A psoriatic arthritis (PsA) core domain set to be measured in randomized controlled trials (RCT) and longitudinal observational studies (LOS) was developed by Group…
Abstract Number: 1607 • 2018 ACR/ARHP Annual Meeting
Achievement of Cdapsa Low Disease Activity or Remission Is Associated with Control of Articular and Extra-Articular Manifestations of Active Psa in Subjects Treated with Apremilast
Laura C. Coates¹, Philip J. Mease², Frank Behrens³, Ana-Maria Orbai⁴, Alexis Ogdie⁵, Michele Brunori⁶, Lichen Teng⁶, Benoit Guerette⁶ and Josef S. Smolen⁷, ¹University of Oxford, Oxford, United Kingdom, ²Swedish Medical Center and University of Washington School of Medicine, Seattle, WA, ³Division of Rheumatology, Goethe University and Fraunhofer IME-TMP, Frankfurt, Germany, ⁴Johns Hopkins University School of Medicine, Baltimore, MD, ⁵University of Pennsylvania, Philadelphia, PA, ⁶Celgene Corporation, Summit, NJ, ⁷Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Therapeutic targets for psoriatic arthritis (PsA) include the achievement of remission (REM) or low disease activity (LDA), measured by the Clinical Disease Activity Index…
Abstract Number: 1608 • 2018 ACR/ARHP Annual Meeting
The Value of Carotid Ultrasound in Cardiovascular Risk Stratification in Patients with Psoriatic Disease
Curtis Sobchak¹, Shadi Akhtari², Paula Harvey², Dafna D Gladman³, Vinod Chandran⁴, Richard J. Cook⁵ and Lihi Eder⁶, ¹Faculty of Medicine, University of Toronto, Toronto, ON, Canada, ²Cardiology, Women's College Hospital, University of Toronto, Toronto, ON, Canada, ³Department of Medicine, Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Krembil Research Institute & University of Toronto, Toronto, ON, Canada, ⁵Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada, ⁶Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Patients with psoriatic disease (PsD) are at a high risk of developing cardiovascular events (CVE). The performance of clinical algorithms for cardiovascular risk stratification,…
Abstract Number: 1609 • 2018 ACR/ARHP Annual Meeting
The Incidence Rate of Spondyloarthritis in Slovenia
Natasa Potocnik Pucelj¹, Alojzija Hočevar¹, Rok Jese¹, Ziga Rotar² and Matija Tomšič³, ¹Department of Rheumatology, University Medical Centre Ljubljana, Ljubljana, Slovenia, ²BioRx.si, Ljubljana, Slovenia, Ljubljana, Slovenia, ³Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
Background/Purpose: Spondyloarthritides (SpA) are heterogeneous group of inflammatory diseases, affecting both, axial and peripheral skeleton. Incidence studies in SpA are sparse. There is no data…
Abstract Number: 1610 • 2018 ACR/ARHP Annual Meeting
Incremental Benefits to Quality of Life Associated with Achieving Higher Levels of American College of Rheumatology Response and Skin Clearance in Patients with Psoriatic Arthritis
Josef S. Smolen¹, David Shrom², Chen-Yen Lin², Julie Birt², Georg Schett³ and Alice B Gottlieb⁴, ¹Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ²Eli Lilly and Company, Indianapolis, IN, ³Medical Clinic 3, Friedrich-Alexander University, Erlangen-Nuremberg, Germany, ⁴Department of Dermatology, New York Medical College, New York, NY
Background/Purpose: PsA is a chronic inflammatory disease associated with psoriasis. For optimal quality of life (QoL) improvements, all PsA symptoms should be managed. We examine…
Abstract Number: 1611 • 2018 ACR/ARHP Annual Meeting
Hospitalizations for Serious Infections in Psoriatic Arthritis Patients: Data from the National Inpatient Sample 2000-2014
Paras Karmacharya¹, Cynthia S. Crowson², Dilli Poudel³, Pragya Shrestha⁴ and Kerry Wright⁵, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Internal Medicine, Reading Hospital-Tower Health System, WEST READING, PA, ⁴Internal medicine, Reading Hospital-Tower Health System, West Reading, PA, ⁵Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Increased risk of infections has been recognized in patients with psoriatic arthritis (PsA) compared to those without PsA. Immunomodulatory effects of PsA, immunosuppressive therapies…
Abstract Number: 1612 • 2018 ACR/ARHP Annual Meeting
Myocardial Infarctions Among Ankylosing Spondylitis Patients in a Large US Insurance Database
Maureen Dubreuil¹, Christine Peloquin², David T. Felson³ and Tuhina Neogi³, ¹Clinical Epidemiology and Rheumatology, Boston University School of Medicine, Boston, MA, ²Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA, ³Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Risk of myocardial infarction (MI) is estimated to be increased up to 60% in ankylosing spondylitis (AS). Studies in patients with rheumatoid arthritis, psoriatic…
Abstract Number: 1613 • 2018 ACR/ARHP Annual Meeting
Dactylitis in Early Spondyloarthritis. Baseline Data from a Prospective French National Cohort
Daniel Wendling¹, Clément Prati², Alain Saraux³, Anna Molto⁴, Thao Pham⁵, Maxime Dougados⁶ and Xavier Guillot⁷, ¹Rheumatology, University Hospital - Bourgogne Franche Comté University, Besançon, France, ²Rheumatology, University Hospital - Bourgogne Franche Comté University, Besancon, France, ³Rheumatology, CHU Brest, Brest, France, ⁴Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ⁵Rheumatology Department, Aix-Marseille University, APHM, Marseille, France, ⁶Department of Rheumatology, Paris Descartes University and Cochin Hospital, Paris, France, ⁷PEPITE EA 4267, Bourgogne-Franche-Comté university, Besançon, France
Background/Purpose: Dactylitis is a particular feature shared across the several phenotypical forms of spondyloarthritis (SpA), part of the classification criteria. There are only few data…
Abstract Number: 1614 • 2018 ACR/ARHP Annual Meeting
Prevalence of Sonographic Enthesitis in Patients with Psoriasis without Arthritis and Its Association Risk Factors of Psoriatic Arthritis
Anwar Albasri¹, Justine Y. Ye², Cheryl F. Rosen³, Vinod Chandran², Dafna D Gladman⁴ and Lihi Eder⁵, ¹Rheumatology, University of Toronto, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁴Department of Medicine, Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ⁵Women's College Research Institute, University of Toronto, Women's College Hospital, Toronto, ON, Canada
Background/Purpose: Enthesitis is one of the hallmarks of psoriatic arthritis (PsA) and may be the initial site of musculoskeletal inflammation. Enthesitis affects up to 50…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].